Chris Counter

Chris Counter

Duke University

H-index: 60

North America-United States

About Chris Counter

Chris Counter, With an exceptional h-index of 60 and a recent h-index of 35 (since 2020), a distinguished researcher at Duke University, specializes in the field of oncogenesis.

His recent articles reflect a diverse array of research interests and contributions to the field:

p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis

p53 dosage impedes KrasG12D-and KrasQ61R-mediated tumorigenesis

Non-canonical genomic driver mutations of urethane carcinogenesis

An ultra-sensitive method to detect mutations in human RAS templates

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis

Distinct responses to rare codons in select Drosophila tissues

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

Chris Counter Information

University

Position

Medical Center

Citations(all)

26334

Citations(since 2020)

4918

Cited By

23034

hIndex(all)

60

hIndex(since 2020)

35

i10Index(all)

93

i10Index(since 2020)

69

Email

University Profile Page

Duke University

Google Scholar

View Google Scholar Profile

Chris Counter Skills & Research Interests

oncogenesis

Top articles of Chris Counter

Title

Journal

Author(s)

Publication Date

p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis

Plos one

Özgün Le Roux

Jeffery I Everitt

Christopher M Counter

2024/3/28

p53 dosage impedes KrasG12D-and KrasQ61R-mediated tumorigenesis

bioRxiv

Özgün Le Roux

Jeffery I Everitt

Christopher M Counter

2023

Non-canonical genomic driver mutations of urethane carcinogenesis

Plos one

Siqi Li

Christopher M Counter

2022/4/28

An ultra-sensitive method to detect mutations in human RAS templates

Small GTPases

Siqi Li

Christopher M Counter

2022/12/31

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis

Elife

Özgün Le Roux

Nicole LK Pershing

Erin Kaltenbrun

Nicole J Newman

Jeffrey I Everitt

...

2022/9/7

Distinct responses to rare codons in select Drosophila tissues

Elife

Scott R Allen

Rebeccah K Stewart

Michael Rogers

Ivan Jimenez Ruiz

Erez Cohen

...

2022/5/6

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

Cell reports

Jennifer E Klomp

Ye S Lee

Craig M Goodwin

Björn Papke

Jeff A Klomp

...

2021/11/30

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

Nature communications

Hema Adhikari

Walaa E Kattan

Shivesh Kumar

Pei Zhou

John F Hancock

...

2021/9/9

Signaling levels mold the RAS mutation tropism of urethane

Elife

Siqi Li

Christopher M Counter

2021/5/17

Using BioID to characterize the RAS interactome

Hema Adhikari

Christopher M Counter

2021/5/12

Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway

Scientific Reports

Jackson Peterson

Siqi Li

Erin Kaltenbrun

Ozgun Erdogan

Christopher M Counter

2020/12/17

Exploiting codon usage identifies intensity-specific modifiers of Ras/MAPK signaling in vivo

PLoS Genetics

Jessica K Sawyer

Zahra Kabiri

Ruth A Montague

Scott R Allen

Rebeccah Stewart

...

2020/12/9

See List of Professors in Chris Counter University(Duke University)